Hookipa Pharma (NASDAQ:HOOK) Announces Earnings Results, Beats Expectations By $0.07 EPS

Hookipa Pharma (NASDAQ:HOOK) announced its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.07, MarketWatch Earnings reports. Hookipa Pharma had a negative net margin of 360.38% and a negative return on equity of 67.34%. The business had revenue of $3.62 million for the quarter, compared to the consensus estimate of $2.56 million.

Shares of HOOK opened at $8.24 on Friday. Hookipa Pharma has a twelve month low of $5.80 and a twelve month high of $14.76. The company has a market cap of $159.32 million and a P/E ratio of -0.77. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.08. The company’s fifty day simple moving average is $11.07 and its 200-day simple moving average is $9.57.

In other news, insider Igor Matushansky sold 5,500 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $12.73, for a total value of $70,015.00. Following the transaction, the insider now directly owns 53,398 shares in the company, valued at $679,756.54. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Klaus Orlinger sold 8,500 shares of the company’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.30, for a total transaction of $96,050.00. Following the completion of the transaction, the vice president now owns 7,358 shares in the company, valued at $83,145.40. The disclosure for this sale can be found here. In the last three months, insiders sold 34,143 shares of company stock worth $414,033.

Several brokerages have recently weighed in on HOOK. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Hookipa Pharma in a research note on Friday, January 10th. Zacks Investment Research raised shares of Hookipa Pharma from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a research note on Friday. ValuEngine raised shares of Hookipa Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, March 3rd. Finally, BidaskClub downgraded shares of Hookipa Pharma from a “buy” rating to a “hold” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $15.81.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Featured Article: How big is the FinTech market?

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.